Energyvet Annovet: Veterinary Product Profile

Energyvet Annovet is a named branded product for All animal species according to the current manufacturer page, including dogs and cats; manufacturer positioning is kept separate from independent clinical and regulatory evidence.

30 mL oral liquid concentrate. Intended species: All animal species according to the current manufacturer page, including dogs and cats.

The current official composition lists a concentrated herbal extract containing 90% Annona muricata, plus cellulose, water, xanthan gum, citric acid, and potassium sorbate. This is the public manufacturer formulation, not an independent assay, and the country-specific label should be checked for changes.

Energyvet markets Annovet as a concentrated graviola preparation for adjunctive discussion in cancer, immune, and geriatric contexts. The page uses cytotoxic and apoptosis-related language and presents the product through the company's holistic veterinary system. Those statements are manufacturer positioning and are not equivalent to a clinical finding in a naturally occurring canine or feline tumor.

May be discussed only as supportive care within a veterinarian-led plan; it must not replace diagnosis, staging, standard treatment, symptom control, or emergency care.

Define a modest supportive objective, baseline, review date, adverse-event plan, and stopping rule with the veterinarian.

Bring the current label, lot, full ingredient panel, country version, complete diet, medicines, and supplements to the treating veterinarian.

The official pages establish identity, form, broad intended species, composition, and manufacturer cautions. No controlled clinical oncology trial of the finished Annovet product in dogs or cats was identified. Cell-culture, constituent, rodent, human, or graviola literature cannot establish that this formulation shrinks tumors, prevents metastasis, improves treatment response, or lengthens survival.

The current manufacturer page states that Annovet can lower blood pressure. Hypotension, cardiovascular disease, blood-pressure medicines, anaesthesia, pregnancy, neurologic signs, gastrointestinal intolerance, liver or kidney disease, and concurrent oncology treatment therefore require veterinary review. A complete current warning panel is not exposed in the HTML page; the linked current leaflet and supplied physical label must control. This entry does not reproduce a manufacturer timing schedule or dose.

No universal compatibility conclusion is made. Review the complete label and individualized treatment plan with the veterinarian.

The manufacturer presents Annovet as a veterinary product in the Czech Republic. An authorisation for this exact name was not identified in the current Czech register of authorised veterinary medicinal products, and no EU oncology-medicine authorisation was verified. Its precise non-medicinal national product category should be confirmed from the current label; manufacturer use language does not establish authorised antineoplastic status.

Czech Republic; European Union

Record the exact bottle, lot, country label, start date, blood-pressure history, medicines, and intended supportive goal. Track appetite, vomiting, stool, alertness, gait, weakness, blood pressure when clinically indicated, weight, and treatment tolerance. The veterinarian should set a stop rule and maintain diagnosis-specific examinations, bloodwork, imaging, or pathology follow-up.